
Amplia Therapeutics has received US FDA clearance for its Investigational New Drug (IND) application, marking a pivotal moment for their best-in-class FAK inhibitor, narmafotinib. The approved trial will assess narmafotinib's safety, tolerability, and efficacy when combined with the widely-used FOLFIRINOX chemotherapy regimen for pancreatic cancer. Amplia's ongoing clinical trial in Australia and South Korea, pairing narmafotinib with gemcitabine and Abraxane®, continues. CEO Dr. Chris Burns expresses the significance of FDA clearance, emphasizing plans to explore narmafotinib's potential in enhancing FOLFIRINOX effectiveness, positioning it as a preferred treatment for pancreatic cancer.
Like
Save
Share